Immunotherapy is one of the most recent and effective cancer treatments. It causes the immune system to identify tumours as intruders in the body and attack them. However, not all patients benefit from immunotherapy. Why? Scientists are not always sure.
Ultrasound is a potential cancer treatment tool. Unlike laser light, which is employed in photodynamic cancer therapy, ultrasonic waves may penetrate deep into tissue (up to 12 cm) to treat deep tumours while causing no harm to healthy cells.
Researchers discovered that 42 percent of patients with metastatic brain cancer benefited from the immune checkpoint inhibitor pembrolizumab in a phase 2 clinical study, with seven patients living for more than two years. The authors emphasise that these advantages must be balanced against t
A new study provided a deeper understanding of the vast diversity of T cell states, as well as their relationships and roles within the complex tumour microenvironment, bringing a new perspective to understanding immunotherapy efficacy in cancer.
Gurgaon (Haryana) [India], May 12 (ANI/BusinessWire India): Art of Healing Cancer, one of the leading organizations focused on precision oncology to treat cancer patients, is raising awareness about the high cost of immunotherapy treatment in India by sharing important information on the sub
A researcher at the University of Central Florida College of Medicine has created a novel, more accurate therapy for a leading source of sickness worldwide each year - acute respiratory virus infections.
he immune system's T cells undergo a process known as T cell exhaustion when they are constantly stressed out as a result of cancer or other chronic disorders. Without functioning T cells, which destroy tumour cells, our bodies are unable to combat cancer. In order to increase the immune sys
The survival rate for people with advanced bladder cancer is less than a year, making it the fourth most common cancer diagnosed in men. The bladder cancer patients who will benefit from immunotherapy are unknown to doctors.
Children with recurrent brain tumours tolerated the first in-human trial of a novel immunotherapy well, and many were able to experience unexpected months of a more normal life, according to researchers. Immunotherapy disables a natural enzyme that tumours hijack for their defence.
A startling 89 per cent of desmoplastic melanoma patients in a nationwide clinical study responded to immunotherapy (pembrolizumab) alone, indicating that many patients could avoid the potential side effects of combination therapies and achieve disease control with this course of treatment.